[Lisheng Pharmaceuticals: application for listing of non-BUBUSTAR APIs] FIFA News Agency, June 14, Lisheng Pharmaceutical announced that the company approved the listing application for non-BUBUSTAR APIs. Clinical studies have shown that Felastat is safe and effective in the treatment of gout patients with hyperuricemia.